Serum Institute of India eager to step into Sanofi's shoes with IPV upscale
Keen to take French pharm major Sanofi (Euronext: SAN) head-on, the Serum Institute of India (SII) is to scale up supplies to fulfil India's entire annual demand for injectable inactivated poliomyelitis vaccines (IPV).
In December 2023, Sanofi halted the production of its IPV brand, ShanIPV. Sanofi had previously announced the discontinuation of ShanIPV due to manufacturing and marketing issues.
Additionally, Sanofi shuttered some of its manufacturing facilities in Telangana. Sanofi's move was reportedly alleged to be linked to its failure to secure a substantial contract for the Shan5 vaccine. Sanofi's decision affected two India-based vaccine manufacturing sites that supplied its IPV vaccine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze